Procurement Summary
Country: Germany
Summary: Open House Biologics Discount Agreements 2025-23 - Etanercept
Deadline: 30 Apr 2026
Posting Date: 23 Mar 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 138300298
Document Ref. No.: 198112-2026
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
CPV Classification
33600000 - Pharmaceutical products
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_detailsLogin to see details
Tender Details
The health insurance companies involved pursue the goal of concluding discount agreements with all suitable pharmaceutical companies in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Etanercept. The contract is concluded as part of the open house biologics process participating health insurance companies: There will be no individual negotiations about the content of the contract; uniform conditions apply. The health insurance companies involved do not guarantee individual contractual partners any exclusivity. The contract term is a maximum of 24 months starting October 1st, 2025. The contract ends on September 30, 2027 at the latest, regardless of the date of conclusion of the contract. All further information can be found in the participation and contract documents. Open House Biologics Discount Agreements 2025-23 - Etanercept The aim is to conclude drug discount contracts in accordance with Section 130a Paragraph 8 SGB V for the active ingredient etanercept as part of an open house procedure. Doc Title: Open House Biologics Discount Agreements 2025-23 - Etanercept Contract Type: supplies
Document Type: Contract Notice Reference Number: OB-2025-23 Contract Type: supplies Authority Type: body-pl-cga Doc Title: Open-House-Biologika-Rabattverträge 2025-23 - Etanercept Dispatch Date: 2026-03-19 Publish Date: 2026-03-23 Submission Date: 2026-04-30
Documents
Tender Notice